Vyleesi
®
product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth.
Click here to learn more ›
Skip to content
Investors
Menu Toggle
Overview
Press Releases
Investor Resources
SEC Filings
Corporate Governance
Reporting Hotline
Webcasts
Contact Us
About Us
Our Science
Our Pipeline
Resources
Join Us
About Us
Our Science
Our Pipeline
Resources
Investors
Menu Toggle
Investors Overview
Press Releases
Investor Resources
SEC Filings
Corporate Governance
Reporting Hotline
Webcasts
Join Us
Contact Us
Privacy Policy
Terms of Use
Main Menu
About Us
Our Science
Our Pipeline
Resources
Investors
Menu Toggle
Investors Overview
Press Releases
Investor Resources
SEC Filings
Corporate Governance
Reporting Hotline
Webcasts
Join Us
Contact Us
Privacy Policy
Terms of Use
Past
Palatin Technologies Fourth Quarter & Fiscal Year End 2023 Teleconference & Webcast
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
Palatin Technologies Third Quarter Fiscal Year 2023 Financial Teleconference and Webcast
Palatin Technologies: Review of Phase 3 PL9643 Data for Dry Eye Disease
Second Quarter Fiscal Year 2023
First Quarter Fiscal Year 2023
Fourth Quarter & Fiscal Year End 2022
Palatin Technologies Third Quarter Fiscal Year 2022
KOL Webinar on Dry Eye Disease
Posts navigation
1
2
Next Page
→
Scroll to Top
